ferritin heavy chain 1 pseudogene 5Genealiases: FTHL5 · FTHP1
Q-omics provides the consensus-scored FTH1P5 profile across patient tissues and cancer cell-line models. FTH1P5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FTH1P5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FTH1P5 RNA expression shows 15,158 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KICH, and KIRC as cancer lineages where FTH1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTH1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTH1P5 survival associations across molecular data types. FTH1P5 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTH1P5 RNA expression–survival associations across cancer types. High FTH1P5 expression shows unfavorable associations in KICH, KIRP, UCEC, LGG, LIHC and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FTH1P5 RNA expression.
This table summarizes FTH1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FTH1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTH1P5 shows lower tumor expression in COAD and READ and higher tumor expression in KIRC, HNSC, LIHC and THCA. The KIRC box plot shows higher FTH1P5 RNA expression in tumor versus normal tissue (log2 FC = +0.988, t-test p < 0.001).
This table shows molecular features associated with FTH1P5 in patient tissues and cancer cell lines. In patient samples, FTH1P5 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set. In cancer cell lines, FTH1P5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
